| 產(chǎn)品名稱 |
QCRL-3 |
| 商品貨號(hào) |
B165543 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Tissue |
spleen |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Carcinoma |
| Strain |
Strain: BALB/c (B cell); BALB/c (myeloma) |
| Applications |
The antibody reacts with MRP (multidrug resistance protein). |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against a multidrug resistance protein (MRP) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against a multidrug resistance protein (MRP) |
| Comments |
Animals were immunized with the multidrug resistant, small cell lung carcinoma, cell line H69AR (ATCC CRL-11351). Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. The antibody reacts with MRP (multidrug resistance protein). MRP is a 190,000 integral membrane phosphoglycoprotein that is overexpressed in some drug-selected resistant cell lines and has been shown to cause multidrug resistance in transfected cells. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 3 to 4 days |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype |
mouse IgG2a kappa |
| Name of Depositor |
Queen's University at Kingston |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Deeley RG, Cole SP. Antibodies to a multidrug resistance protein. US Patent 6,063,621 dated May 16 2000
Hipfner DR, et al. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 54: 5788-5792, 1994. PubMed: 7954400
|
